{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:34:31Z","timestamp":1785764071395,"version":"3.56.0"},"reference-count":32,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2017,3,12]],"date-time":"2017-03-12T00:00:00Z","timestamp":1489276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anthracycline-based chemotherapy is used in many malignancies. Current recommendations by several groups suggest cardiac monitoring prior to and during anthracycline therapy. We aim to review the usefulness of baseline cardiac screening for left ventricular ejection fraction to assess if it had any impact on chemotherapy decisions in patients to be treated with anthracycline-based regimens or any beneficial effect upon outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective three-year audit of cancer patients who underwent GBPS prior to anthracycline (doxorubicin) chemotherapy. Subjects were identified via records from the Department of Nuclear Medicine. Pharmacy dispensing records identified those who received doxorubicin. Patient demographics, cancer type, cardiac risk factors, GBPS ejection fraction (EF), and cumulative anthracycline dose were collected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From 1 August 2009 to 31 July 2012, 179 patients underwent GBPS pre-doxorubicin chemotherapy. The mean age was 59 years (range 21\u201389 years), with 51% being males. Only two patients (1.1%) had an abnormal EF\u2009&lt;\u200950%, while 33 patients (18%) had an EF 51\u201359% and 144 patients (80%) had EF\u2009\u2265\u200960%. The two patients with reduced baseline EF still received anthracycline-based chemotherapy. All 135 patients without any known cardiovascular risk factors had normal EFs. The total number of patients who received anthracycline chemotherapy during the same period was 207. Thus 28 patients (13%) commenced anthracycline without a prior GBPS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Only 1.1% of the screened patients had EF\u2009&lt;\u200950%. These two patients still received doxorubicin chemotherapy despite a compromised EF, as their treating clinicians believed that the benefits of chemotherapy outweighed the risk of potential cardiac toxicity. Our audit questions the practice of routine cardiac evaluation pre-anthracycline screening with GBPS. We propose that routine screening only be requested if cardiac risk factors are present.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155217697487","type":"journal-article","created":{"date-parts":[[2017,3,13]],"date-time":"2017-03-13T02:57:29Z","timestamp":1489373849000},"page":"264-271","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["The utility of routine pre-chemotherapy screening with cardiac gated blood pool scan for patients at low risk of anthracycline toxicity"],"prefix":"10.1177","volume":"24","author":[{"given":"Puey Ling","family":"Chia","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, St Vincent\u2019s Hospital Melbourne, Melbourne, Australia"},{"name":"Department of Medical Oncology, Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Chiang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, St Vincent\u2019s Hospital Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Snyder","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, St Vincent\u2019s Hospital Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Dowling","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, St Vincent\u2019s Hospital Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2017,3,12]]},"reference":[{"key":"bibr1-1078155217697487","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I"},{"key":"bibr2-1078155217697487","first-page":"3024","volume":"33","author":"Gottlieb JA","year":"1973","journal-title":"Cancer Res"},{"key":"bibr3-1078155217697487","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66544-0"},{"key":"bibr4-1078155217697487","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.2.658"},{"key":"bibr5-1078155217697487","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055531"},{"key":"bibr6-1078155217697487","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1161\/01.CIR.0000080946.42225.4D","volume":"108","author":"Klocke FJ","year":"2003","journal-title":"Circulation"},{"key":"bibr7-1078155217697487","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds293"},{"key":"bibr8-1078155217697487","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jeu192"},{"key":"bibr9-1078155217697487","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1407-6"},{"key":"bibr10-1078155217697487","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605382"},{"key":"bibr11-1078155217697487","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2010.11.001"},{"key":"bibr12-1078155217697487","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.5.6.791"},{"key":"bibr13-1078155217697487","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.11.3596"},{"key":"bibr14-1078155217697487","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-197701010-00002"},{"key":"bibr15-1078155217697487","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103153441101"},{"key":"bibr16-1078155217697487","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-91-5-710"},{"key":"bibr17-1078155217697487","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn206"},{"key":"bibr18-1078155217697487","first-page":"21","volume":"7","author":"Valachis A","year":"2015","journal-title":"Breast Cancer"},{"key":"bibr19-1078155217697487","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(87)90212-9"},{"key":"bibr20-1078155217697487","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.05.019"},{"key":"bibr21-1078155217697487","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11407"},{"key":"bibr22-1078155217697487","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf132"},{"key":"bibr23-1078155217697487","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1161\/01.CIR.0000073597.57414.A9","volume":"108","author":"Cheitlin MD","year":"2003","journal-title":"Circulation"},{"key":"bibr24-1078155217697487","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2012.000682"},{"key":"bibr25-1078155217697487","first-page":"1","volume":"56","author":"Bryant A","year":"2014","journal-title":"Leuk Lymph"},{"key":"bibr26-1078155217697487","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-014-1004-0"},{"key":"bibr27-1078155217697487","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0449"},{"key":"bibr28-1078155217697487","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-200108000-00027"},{"key":"bibr29-1078155217697487","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2011.07.006"},{"key":"bibr30-1078155217697487","unstructured":"eviQ. Cardiac Toxicity associated with Anthracyclines, https:\/\/www.eviq.org.au\/AdditionalClinicalInformation\/tabid\/64\/id\/22\/Default.aspx?popup=1 (accessed 30 September 2016)."},{"key":"bibr31-1078155217697487","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.11.3502"},{"key":"bibr32-1078155217697487","first-page":"54","volume":"11","author":"Crossley RJ","year":"1984","journal-title":"Semin Oncol"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155217697487","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155217697487","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155217697487","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:17:14Z","timestamp":1777688234000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155217697487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,12]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1177\/1078155217697487"],"URL":"https:\/\/doi.org\/10.1177\/1078155217697487","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,12]]}}}